Geron (GERN)
(Delayed Data from NSDQ)
$4.14 USD
+0.35 (9.23%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $4.24 +0.10 (2.42%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GERN 4.14 +0.35(9.23%)
Will GERN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for GERN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GERN
Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Company News for Mar 18, 2024
GERN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Geron (GERN) Gets ODAC Votes for Blood Disorder Drug, Shares Up
Implied Volatility Surging for Geron (GERN) Stock Options
Geron (GERN) Upgraded to Buy: Here's Why
Other News for GERN
Navigating 10 Analyst Ratings For Geron
Geron initiated with bullish view at TD Cowen, here's why
TD Cowen starts Geron at buy, cites imetelstat market potential
3 'Buy-Rated' Biotech Stocks Under $10
Skechers Reports Upbeat Earnings, Joins Tutor Perini, AppFolio, Newell Brands And Other Big Stocks Moving Higher On Friday